Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644557 | 1.00 | NTRK1 (0.43) | NTRK1HDAC1HDAC2RIPK1NR1H2 | |
| SCHEMBL28678669 | 0.85 | RIPK1 (0.40) | RIPK1 | |
| SCHEMBL28673502 | 0.85 | RIPK1 (0.40) | RIPK1 | |
| SCHEMBL24714794 | 0.85 | RIPK1 (0.43) | NTRK1RIPK1 | |
| SCHEMBL22638847 | 0.85 | RIPK1 (0.55) | HDAC1HDAC2RIPK1NR1H2 | |
| SCHEMBL22638892 | 0.85 | RIPK1 (0.55) | HDAC1HDAC2RIPK1NR1H2 | |
| SCHEMBL30968268 | 0.84 | RIPK1 (0.37) | NTRK1RIPK1 | |
| SCHEMBL22638879 | 0.83 | NTRK1 (0.41) | NTRK1HDAC1HDAC2NR1H2SMN1; SMN2 | |
| SCHEMBL22638942 | 0.82 | RIPK1 (0.44) | HDAC1HDAC2RIPK1NR1H2 | |
| SCHEMBL22638855 | 0.81 | RIPK1 (0.39) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767092-B | Di-heterocyclic carbonyl substituted dihydropyrazoles, their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3967682-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | NTRK1 1263/4885HDAC1 403/4885HDAC2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.